<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 360 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page359.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=360">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 360 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 360</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=360"><img src="../thumb/360.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>Cytostatics - 23                                                               2020-04 / 323
       714757-001: 100 mg, 1x16,7 ml vial, R435,74  (S4) CONC.SOL.FOR DILUT.FOR INFUS, 46/26/0487, 0488,0489.   TAGRISSO, Astra Zeneca [P/S]
       714758-001: 300 mg, 1x50 ml vial, R1 304,59  2 mg/ml       Osimertinib
       For further details refer to manufact.prod.lit.  721800-001: 10 mg/5 ml, 1 vial, R77,51  Indications: Loc.advanc./metastat.EGFR T790M mutat.-posit.non-
                                     721801-001: 50 mg/25 ml, 1 vial, R382,55  small cell lung Ca (NSCLC) predomin. bronch.adenocarcinoma whose
       PECASET, (Eurolab) Accord [P/S]  721802-001: 200 mg/100 ml, 1 vial, R1550,20  dis. progress. on/aft.EGFR TK1 ther.
       Capecitabine                  For further details refer to manufact.prod.lit.  (S4) TABS, 51/26/0927,0928
       Indications: Loc.advanc./metastat.breast Ca: Combinat. ther.  3000923-001: 40 mg, 30, R91 990,80
       with docetaxel aft.fail.of cytotox. ther. incl.an anthracycline. Mono-  SANDOZ VINORELBINE, Sandoz [P/S]  3000924-001: 80 mg, 30, R91 990,80
       ther.aft.fail.of taxanes and an anthracycline contain.chemother.   Vinorelbine  For futher details refer to prof. info.
       regim./ where anthracycline ther.not further indicat.  Indications: Palliat.treatm.of advanc.inoper.non-small cell lung Ca
       Colorect.Ca: Adjuv.aft.surg.in Dukes C colon Ca., metastat.colo-  as a sngl.agent/in combinat. Combinat.ther.proves more effect.than   TARCEVA, Roche
                                                            st
       rect.adenocarcinoma (benef.relates to time to progress.while over-  monother. Metastat.breast Ca in pts.where anthracycline 1  line mono-  Erlotinib HCl.
       all surviv.not influenc.)     ther.has fail.or relaps.within.6 mnths.of anthracycline-based adjuv.ther.  Indications: Loc.advanc./metastat.non-small cell lung Ca aft.fail.of
                                                                                   st
       Gastric Ca: 1  line treatm.of advanc.gastric adenocarcinoma in   (S4) CONC.FOR SOL.FOR INFUS. 42/26/0132, 0133. 10 mg/ml.  at least one prior chemother. regimen., 1  line treatm of loc.advanc./
             st
       combinat.with other anti-chemotherapeut. regim.(benef.relates to   721304-001: 10 mg, 1x1 ml vial, R221,58  metastat. (stage IV) bronch.adenocarcin.demonstrat.EGFR activat.mu-
       time to progress.while overall surviv.not influenc.)  721305-001: 50 mg, 1x5 ml vial, R1 108,07  tat in pts.who have never smoked & with ECOG perform.stat.of 0-1,
                                     For further details refer to manufact.prod.lit.
                                                                   st
       (S4) TABS, 49/26/0681, 0682                                1  line treatm.of loc. advanc. unresectab./ metastat. pancreat.Ca in
       722962-001: 150 mg, 60, R468,81  SPRYCEL, Equity [P/S] &   combinat.with gemcitabine,
       722963-001: 500 mg 120, R3 244,45  Dasatinib               (S4) TABS. A40/26/0359, 0360, 0361.
       For further details refer to professional info.  Indications: New diagnos.Philadelphia chromosome-posit.chron.  712628-001: 25 mg, 30, R7 370,84
                                                                  712633-001: 100 mg, 30, R23 580,19
       PEMETREXED ACCORD 500, Accord [P/S]  myeloid leukaem.in chron.phase, chron.accelerat.or myeloid or lym-  712634-001: 150 mg, 30, R27 640,62
                                     phoid blast phase chron.myeloid leukaem.in adults resist./intol.to pri-
       Pemetrexed                    or ther.incl.imatinib, Philadelphia chromosome-posit.ac.lymphoblast.   For further details refer to manufac.prod.lit
       Indications: Malign.pleur.mesothelioma in combinat. with cis-  leukaem.in adults resist./intol.to prior ther.  TASIGNA, Novartis &
       platin, monother.in loc.advanc./ metastat. non-small cell lung Ca   (S4) TABS, 41/26/1039, 1040, 1041, 44/26/0205  Nilotinib
       aft. prior chemother., in combin.with cisplatin for init. treatm. of   711441-001: 20 mg, 60, R9 155,72  Indications: Treatm.of adult pts.with newly diagn.Philadelphia
       loc.advanc.or metastat.non-small cell lung Ca other than predom.  711442-001: 50 mg, 60, R22 889,32  chromosome posit.chron. myelogen. leukaem.(Ph+ CML) in chron.
       squamous cell histol.         711443-001: 70 mg, 60, R31 993,77  phas., treatm. of chron./accelerat.phas. Philadelphia chromosome
       (S4) LYOPHIL.POWD.FOR SOL.FOR INFUS, 49/26/0888   718478-001: 100 mg, 30, R22 889,32  posit.chron.myelogen.leukaem.(Ph+ CML) in adult pts. resist./ intol.
       723384-001: 500 mg, 1x20 ml vial, R9 992,30  For further details refer to manufact.prod.lit.  to at least one prior ther.incl. imatinib.
       For further details refer to manufact.prod.lit.  See also MDR page 290.  (S4) CAPS, 45/26/0410, 41/26/0973
       PROVERA, Pfizer [P/S]         STIVARGA 40 mg, Bayer        719121-001: 150 mg, 112, R22 596,55
       Medroxyprogesterone acetate.  Regorafenib                  714086-001: 200 mg, 112, R30 128,72
       Indications: Palliat.treatm.of recurr./metastat. endometr.& ren.Ca   Indications: Metastat.colorect.Ca (CRC) prev. treat.with/not can-  For further details refer to manufact.prod.lit.
       or breast Ca in post-menopaus. women.  didates for fluoropyrimidine-bas. chemother., an anti-VEGF ther.& if   See also MDR page 578.
       (S4) TABS. S/21.8.2/1, W/21.8.2/462  KRAS wild type an anti-EGFR ther., gastrointestin.stromal tumours   TEMINTAS, Eurolab [P/S]
       757942-008: 100 mg, 100, R1 529,14  (GIST) prev.treat.with 2 tyrosine kinase inhibit.  Temozolomide
       702084-007: 500 mg, 100, R3 271,99  (S4) TABS, 47/26/1005.  Indications: Recurr.malign.glioma, advanc. metast.malign.melanoma.
       Dosage: Endometr./ren.Ca: 200-600 mg/day.  720787-001: 40 mg, 28, R53, 245,92  (S4) CAPS. 44/26/0964, 0965, 0966, 0967
       Breast Ca: 400-1 200 mg/day.  For furth.details refer to manufacturers product lit.  718095-001: 5 mg, 5, R112,81
       Side effects: Anaphylax., thrombo-embol. disords., nervousn., in-  SUNMATIN, Ranbaxy [P/S]  718096-001: 20 mg, 5, R451,21
       somn., somnol., fatig., depress., dizzin., headache, skin rash, acne,   Imatinib  718097-001: 100 mg, 5, R2 256,11
       hirsut., alopec., naus., breast tendern., weight change, moonface.,   Indications: Adults & paed.pts: New.diagn Philadelph. chromo-  718098-001: 250 mg, 5, R5 579,80
       urticar., prurit., galactorrh., pyrex.  some posit.chron.myeloid leukaem (CML)., CML in blast crisis/accel-  For further details refer to manufact.prod.lit.
       Special precautions: Diab., condit.affect.by weight gain/fluid re-  erat./ chron. phase aft.interferon-alpha ther.fail. Adults: Unresect.&/  TEMODAL, MSD [P/S]
       tent., ment.depress.hist., cushingoid sympts., if endometr./ endocer-  or metastat.malign.gastrointest. stromal tumours (GIST).
       vic. tiss.submit.for examin.inform patholog.of pts.ingest.of meds.  Safety & effic.not est.for more than 14 mnths.in CML 1 -line ther.  Temozolomide
                                                            st
                                                                  Indications: New.diagnos.glioblastoma multiforme aft.debulk.surg.
       PURI-NETHOL, (Aspen Pharmacare: Pharma) Pharmacare [P/S]  (S4) TABS, 44/26/0886, 0887  concom.with radiother. & then as adjuv.treatm.in adults, recurr.malign.
                                     719926-001: 100 mg, 60, R6 546,95
       Mercaptopurine.               719927-001: 400 mg, 30, R12 592,50For further details refer to   glioma, advanc. metast.malign.melanoma.
       Indications: Ac.leukaem., value in ac. lymphoblast. leukaem.,   manufact.prod.lit.  (S4) CAPS. 32/26/0721, 0722, 0723, 42/26/0961, 0962, 32/26/0724
       ac.myelogen.leukaem., chron.granulocyt.leukaem.            859931-005: 5 mg, 5, R95,90
       (S4) TABS. H2751.             SUTENT, Pfizer [P/S] &       859958-019: 20 mg, 5, R479,57
       758302-002: 50 mg, 25, R1 282,15  Sunitinib                859494-004: 100 mg, 5, R1 918,32
       For further details refer to manufact.prod.lit.  Indications: Gastrointestin.stromal tumour aft. fail. of imatinib me-  718312-001: 140 mg, 5, R1 918,32
                                     sylate treatm.due to resist./ intol., treatm.naive advanc.and/or metast.  718313-001: 180 mg, 5, R4 316,21
       REVOLADE, Novartis &          ren.cell Ca, metastat.ren.cell Ca (MRCC) aft.fail.of cytokine-bas. ther.  859966-003: 250 mg, 5, R4 520,19
       Eltrombopag olamine           (inteferon alpha/interleukin-2).  For further details refer to manufact.prod.lit.
       Indications: Thrombocytopen.in adults with chron, idiopath.(im-  (S4) CAPS. 41/26/0197, 0195, 0196.
       mune) thrombocytopen.purpura (ITP) here respons to corticoster./  710179-001: 12,5 mg, 28, R9 915,64  TEREXTA 500, (Eurolab) Accord [P/S]
                                                                  Pemetrexed
       immunoglobul or splenectomy insuffic.  710181-001: 25 mg, 28, R19,830,90  Indications: Malign.pleur.mesothelioma in combinat. with cis-
       (S4) TABS, 44/26/0548, 0549   710182-001: 50 mg, 28, R39 662,36
       3000171-001: 25 mg, 28, R14 190,24  For further info.refer to manuf.product lit.  platin, monother.in loc.advanc./ metastat. non-small cell lung Ca
                                                                  aft. prior chemother., in combin.with cisplatin for init. treatm. of
       3000172-001: 50 mg, 28, R28 380,48  See also MDR page 648.  loc.advanc.or metastat.non-small cell lung Ca other than predom.
       For further details refer to manufact.product lit.         squamous cell histol.
       See also MDR page 565.        TAFINLAR, Novartis [P/S]
                                     Dabrafenib                   (S4) LYOPHIL.POWD.FOR SOL.FOR INFUS, 49/26/0889
       RIBOMUSTIN, Astellas &        Indications: Unresectable/metastat.melanoma with BRAF V600E   723753-001: 500 mg, 1x50 ml vial, R10 681,56
       Bendamustine HCl              mutat.in combinat.with trametinib, advanc.non-small cell adenocar-  For further details refer to manufact.prod.lit.
       Indications: First-line chron.lymphocyt.leukaem. treatm. (Binet   cin. with BRAF V600 mutat.in combinat.with trametinib  TEVA FLUDARABINE, (Cipla Medpro) Teva [P/S]
       stage B or C) in pts.for whom fludarabine combin.chemother.not   (S4) CAPS, 51/32.2/0817, 0818  Fludarabine phosphate
       appropr., 1 st  line treatm.of indol.CD20 posit.non-Hodgkins lym-  3000961-001: 50 mg, 120, R16 207,33  Indications: Treatm.of B-cell chron.lymphocyt. leukaem. pts. who
       phoma in combinat.with rituximab, indol.non-Hodgkin’s lympho-  3000628-001: 75 mg, 120, R24 311,00  have not respond.to/have not progress.dur.treatm.with at least one
       ma.as monother.in pts.who have progress.dur./within 6 mnths.  For further details refer to prod.info.  standard alkylat.agent contain.regimen.
       follow.treatm.with rituximab or a rituximab-cont.regim., front   (S4) CONC.SOL.FOR INJ/INFUS, 43/26/0009 25 mg/ml
       line treatm.of multiple myeloma (Durie-Salmon stage II with   716356-001: 50 mg, 1x2 ml vial, R2 218,03
       progress or stage III) in combin.with prednisone for pts.older   For further details refer to manufact.prod.lit.
       than 65 yrs.not eligible for autolog.stem cell transpl.& who have   Certain medicines (i.e.
       clinic. neuropathy at time of diagn.preclud.use of thalidomide or   TYKERB, Novartis
       bortezomib contain. treatm.         those that cause CNS   Lapatinib
       (S4) POWD.FOR SOL.FOR INFUS. 45/26/1127, 1128. 2,5 mg/ml  depression) may lead to   Indications: In combinat.with capecitabine for advanc/ metastat.
       717665-003: 25 mg, 1x vial, R1 054,61                      breast Ca whose tumours overexpress HER2+/neu (ErbB2+) who have
       710853-001: 100 mg, 1 vial, R4 218,44  drowsiness and impaired   progress. on prior ther.incl.trastuzumab in metastat. sett., in combi-
       For further details refer to manufact.prod.lit.            nat.with paclitaxel for treatm.of metastat. breast cancer whose tu-
       See also MDR page 216.              concentration, which   mours over express HER2+/neu (erb2), in combinat.with aromatase
                                                                  inhibit.for hormone sensit.metastat. breast Ca whose tumours over
       RUBEXET, (Eurolab) Accord [P/S]     may be aggravated by   express HER2+/neu (ErbB2+)
       Doxorubicin HCl.                   the simultaneous intake   (S4) TABS, 42/26/0275. 250 mg
       Indications: Ac.leukaem./lymphom./solid tumours, metastat.ad-  715582-001: 250 mg, 70, R12 457,99
       enocarcin.of breast/ bladd. Ca/ bronchogen.Ca & neuroblastoma,   of alcohol or other   For further details refer to manufact.prod.lit.
       metastat. thyroid Ca/endometr./testes/prostate/cervix/head &   VALTIB, Accord [P/S]
       neck/plasma cell myeloma, wide range of sarcomas incl.osteo-  central nervous system   Bortezomib
       gen./Ewing’s/soft-tiss.sarcom., combinat. regimens for Ca ovary/  depressant agents.  Indications: Prim.treatm.of multip.myeloma in combinat. with mel-
       breast/small (oat)- cell lung Ca/Hodgkin’s dis./non-Hodgkins   phalan & prednisone, monother. for multiple myeloma where at least
       lymphoma.                                                  one prior ther.receiv.& dis.progress.</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page359.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page355.html">355</a>&nbsp;&nbsp;&nbsp;<a href="page356.html">356</a>&nbsp;&nbsp;&nbsp;<a href="page357.html">357</a>&nbsp;&nbsp;&nbsp;<a href="page358.html">358</a>&nbsp;&nbsp;&nbsp;<a href="page359.html">359</a>&nbsp;&nbsp;&nbsp;<a href="page360.html">360</a>&nbsp;&nbsp;&nbsp;<a href="page361.html">361</a>&nbsp;&nbsp;&nbsp;<a href="page362.html">362</a>&nbsp;&nbsp;&nbsp;<a href="page363.html">363</a>&nbsp;&nbsp;&nbsp;<a href="page364.html">364</a>&nbsp;&nbsp;&nbsp;<a href="page365.html">365</a>
             </td>
             <td width="35%"><a href="page361.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page361.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
